Such an added benefit cant be produced from the dossier.

Aflibercept drug used for AMD shows zero added benefit over current standard therapy The drug aflibercept has been approved in Germany since November 2012 for the treating wet age-related macular degeneration . Within an early benefit assessment pursuant to the Action on the Reform of the Market for Medicinal Products the German Institute for Quality and Performance in HEALTHCARE examined whether this new drug offers an added advantage over the existing standard therapy viagra generic . Such an added benefit can’t be produced from the dossier, nevertheless, as the manufacturer did not submit any suitable data for this comparison. Related StoriesTyrogenex announces outcomes from phase 1 study of orally-administered X-82 in individuals with AMDAstellas enters into definitive contract to acquire OcataDiscovery offers promising alternative to current therapies for AMD and ROP Patients in charge group didn’t receive approval-compliant treatment The Federal Joint Committee specified the medication ranibizumab as suitable comparator therapy.